mercredi 17 janvier 2018

Onco Actu du 17 janvier 2018

1. Biologie

High-Fat Diet May Fuel Spread of Prostate Cancer [NY Times]

2.10 Etiologie - Alcool

Healthcare Triage: Alcohol and Cancer and How We Think About Risk [The Incidental Economist]

4. Dépistage, diagnostic et pronostic

Inside the global race to deliver radioactive tracers to detect cancer [STAT]

4.1 Dép., diag. & prono. - Prostate

Blood test which confirms prostate cancer could prevent 70pc of biopsies [The Telegraph]

4.12 Biopsies liquides

Liquid Biopsy Test Shows Promise for Detecting Early-Stage Colorectal Cancer [ASCO]

4.9 Dép., diag. & prono. - Sein

When You Need A Breast Screening, Should You Get A 3-D Mammogram? [KHN]

5. Traitements

Does the oncology community have a rejection bias when it comes to repurposed drugs? [ecancermedicalscience]

The Landscape of Kinase Inhibitors [In the Pipeline]

5.12 Immunothérapies

Who Might Benefit from Immunotherapy? Study Suggests Possible Marker [University of Michigan]

5.12.10 Immunothérapies - Fusions et acquisitions

Juno jumps afterhours as reports suggest Celgene wants a buyout [FierceBiotech]

Juno shares rocket higher on word that Celgene is hunting a buyout deal [EndPoints]

Celgene in Talks to Buy Juno Therapeutics [Wall Street Journal]

5.12.2 Immunothérapies - CAR-T

Researchers Develop a Remote-Controlled Cancer Immunotherapy System [UC San Diego]

Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL [Novartis]

Novartis's Kymriah wins speedy reviews in U.S., Europe [Reuters]

5.12.4 Immunothérapies - Essais

Merck Is Latest to Tout Success as Lung Cancer Drug Combos Plow Forward [Xconomy]

Merck Extends Its Lung Cancer Lead [Bloomberg]

Positive Keytruda lung cancer data sends Merck shares up 6 percent [Reuters]

Merck’s Keytruda combo wows again, acing PhIII overall survival goal for lung cancer early [EndPoints]

Merck's KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (KEYNOTE-189) [Merck]

5.12.8 Immunothérapies - Economie

German watchdog calls for direct comparison of cancer immunotherapies [Reuters]

5.2.1 Pharma - Partenariats

Merck KGaA taps CRUK, ICR for source of cancer candidates [FierceBiotech]

Cancer Research UK and the Institute of Cancer Research, London, join forces with Merck in new drug discovery alliance [Cancer Research UK]

5.2.3 Pharma - économie

Roche CEO Schwan concedes challenges as ‘highly, highly profitable’ drugs fall to biosimilar rivals [FiercePharma]

German drugmaker files $21.6M IPO for skin cancer drug [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Transparency: FDA to Release Portions of Redacted Clinical Study Reports [RAPS]

FDA to release more clinical trial information for newly approved drugs [Washington Post]

FDA commissioner Scott Gottlieb just broke a public promise on publishing CRLs — and yes, it matters [EndPoints]

FDA Commissioner Scott Gottlieb, M.D., on new steps FDA is taking to enhance transparency of clinical trial information to support innovation and scientific inquiry related to new drugs [FDA]

5.5 ASCO

Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma [Exelixis]

Heads Up: 2018 ASCO GI Cancers Symposium [OBR]

Array BioPharma to Present Updated Phase 3 BEACON CRC Safety Lead-In Results of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the 2018 Gastrointestinal Cancers Symposium [Array]

6. Lutte contre les cancers

Why has no other European country adopted the Research Excellence Framework? [LSE Impact Blog]

6.6 Publications

Make replication studies ‘a normal and essential part of science,’ Dutch science academy says [Science]

Science search engine links papers to grants and patents [Nature]